Psilocybin is a psychedelic with
therapeutic potential. While there
is growing evidence that psilocybin exerts its beneficial effects
through enhancing neural plasticity, the exact brain regions involved
are not completely understood. Determining the impact of psilocybin
on plasticity-related gene expression throughout the brain can broaden
our understanding of the neural circuits involved in psychedelic-evoked
neural plasticity. In this study, whole-brain serial two-photon microscopy
and light sheet microscopy were employed to map the expression of
the immediate early gene, c-Fos, in male and female mice. The drug-induced
c-Fos expression following psilocybin administration was compared
to that of subanesthetic ketamine and saline control. Psilocybin and
ketamine produced acutely comparable elevations in c-Fos expression
in numerous brain regions, including anterior cingulate cortex, locus
coeruleus, primary visual cortex, central and basolateral amygdala,
medial and lateral habenula, and claustrum. Select regions exhibited
drug-preferential differences, such as dorsal raphe and insular cortex
for psilocybin and the CA1 subfield of hippocampus for ketamine. To
gain insights into the contributions of receptors and cell types,
the c-Fos expression maps were related to brain-wide in situ hybridization
data. The transcript analyses showed that the endogenous levels of Grin2a and Grin2b predict whether a cortical
region is sensitive to drug-evoked neural plasticity for both ketamine
and psilocybin. Collectively, the systematic mapping approach produced
an unbiased list of brain regions impacted by psilocybin and ketamine.
The data are a resource that highlights previously underappreciated
regions for future investigations. Furthermore, the robust relationships
between drug-evoked c-Fos expression and endogenous transcript distributions
suggest glutamatergic receptors as a potential convergent target for
how psilocybin and ketamine produce their rapid-acting and long-lasting
therapeutic effects.